MDxHealth SA filings document a foreign private issuer focused on precision diagnostics for prostate cancer and other urologic diseases. The company’s Form 6-K reports furnish financial results, interim reports, press releases, governance updates and materials incorporated by reference into registration statements.
The filing record includes shareholder meeting notices, proxy and attendance materials, a share option plan, authorized-capital reports, warrant terms and acquisition-related disclosures. MDXH filings also document the completed Exosome Diagnostics acquisition through audited financial statements and pro forma financial information, along with amendments to earnout obligations related to the GPS acquisition.
MDxHealth is registering up to $200,000,000 of ordinary shares on a shelf basis, allowing primary offerings from time to time, including a $50,000,000 at-the-market program under a sales agreement. A separate secondary prospectus covers 1,867,186 ordinary shares for resale, outside this $200,000,000 capacity.
The company is a commercial-stage precision diagnostics business focused on urologic cancers, with core tests ExoDx, Confirm mdx and GPS. It qualifies as both an emerging growth company and a foreign private issuer, using reduced U.S. reporting requirements.
Risk factors emphasize continued losses and liquidity pressure. As of December 31, 2024, MDxHealth had an accumulated deficit of $369.5 million, a 2024 net loss of $38.1 million and operating cash outflows of $18.5 million, and its financial statements are prepared on a going-concern basis. The company also has a senior secured credit facility of up to $100 million with OrbiMed and outstanding deferred acquisition obligations, including up to $10 million related to Exosome Diagnostics and up to $54.5 million tied to the GPS business, all of which may require substantial future cash or share payments.
MDxHealth reports on its acquisition of Exosome Diagnostics and an amended earnout arrangement for a prior GPS transaction. The company agreed to acquire Exosome Diagnostics, including the ExoDx prostate cancer test and CLIA lab, for up to $15 million, with about $5 million in stock at closing and four subsequent annual instalments of $2.5 million each, partly in cash and partly in cash or stock at MDxHealth’s discretion.
Audited 2025 financials for Exosome Diagnostics show sales of $27.3 million and a net loss of $86.5 million, driven largely by impairment charges. MDxHealth also amended the GPS acquisition earnout with Exact Sciences, rescheduling remaining payments to $15.0 million in 2026, $18.0 million in 2027 and $21.5 million in 2028, and issuing warrants for 3 million MDxHealth shares at an exercise price of $5.265 per share.
MDxHealth SA received an updated ownership report showing that Genomic Health, Inc., a Delaware company and wholly owned subsidiary of Exact Sciences Corporation, beneficially owns a total of 6,441,171 ordinary shares of MDxHealth. This total includes 2,441,171 ordinary shares directly owned and warrants or contractual rights to purchase an additional 4,000,000 ordinary shares.
The filing states this represents 12.0% of MDxHealth’s ordinary shares, based on 49,497,334 ordinary shares issued and outstanding as described in MDxHealth’s Form F-3 registration statement filed on December 29, 2025. Exact Sciences may be deemed to beneficially own the shares held by Genomic Health, and the reporting persons certify that the securities are not held for the purpose of changing or influencing control of MDxHealth.
MDxHealth SA reported preliminary 2025 revenue of about $109 million, with fourth quarter revenue of about $30.5 million, reflecting year-over-year growth of 21% and 23%, respectively. In the quarter, the company billed 11,201 tissue-based and 27,486 liquid-based units, while full-year volumes reached 49,180 tissue-based and 71,920 liquid-based units, with especially strong liquid-based growth. Year-end cash was $29.0 million.
For 2026, MDxHealth guides revenue to $137–140 million, implying growth of about 26–28%, and targets an adjusted EBITDA margin run rate of 10% exiting 2026. The company also amended the earnout related to its 2022 GPS acquisition from Exact Sciences, deferring payments into three installments of $15.0 million in 2026, $18.0 million in 2027, and $21.5 million in 2028, and agreed to issue warrants for 3 million shares at an exercise price of $5.265 per share.
MDxHealth SA submitted a Form 6-K as a foreign private issuer to provide its 2025 Interim Report to investors. The interim report is attached as Exhibit 99.1 and contains the company’s detailed mid-year financial and operational information.
The company also formally confirms the accuracy of its previously released preliminary financial results that were furnished in a prior Form 6-K on August 5, 2025. The interim report is incorporated by reference into MDxHealth’s existing shelf registration statements on Form F-3, meaning those registration statements now include the latest interim information.